Item 5.02. Departure of Directors or Principal Officer; Election of Directors; Appointment of Principal Officers.

On September 5, 2012, the board of directors of MultiCell Technologies, Inc. (the "Company") appointed D. Scott Lukeman Ph.D. to the board of directors to serve until his successor is duly appointed or elected. In connection therewith, the board of directors granted to Dr. Lukeman an option to purchase 1.0 million shares of the Company's common stock at an exercise price per share of $.0014, the closing price of the Company's common stock on September 5, 2012, as reported on the over the counter bulletin board. The option has a 5-year term, and 1/36thof the shares underlying the option vest on the last day of each month following the date of the grant over the next three years, so long as Dr. Lukeman continues to be a service provider to the Company. Dr. Lukeman's options will be governed by the Company's 2004 Equity Incentive Plan.

Dr. Lukeman received his Ph.D. in Pharmacology/Cellular and Molecular Biology from the University of Miami, after earning a B.A. in Natural Sciences from New College of Florida. From 1993 to present Dr. Lukeman has served as Strategic & Management Consultant to Provident Group Consulting. From 1990 to 1992 Dr. Lukeman was Cardiovascular Area Leader fo Italfarmaco, in Milan, Italy. He was Group Leader, Soluble Peptides at Telios Pharmaceuticals in San Diego, CA from 1988 to 1990.

Item 9.01 Exhibits

( c ) Exhibits

99.1 Press Release dated September 6, 2012.